Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Real-World Study of Mirvetuximab Soravtansine (MIRV) in Ovarian Cancer Patients of Expression of Folate Receptor α (MIRAS)

1. juli 2026 opdateret af: NING LI-GYN

A Real-World Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (MIRV) in Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer With Expression of Folate Receptor α

Mirvetuximab soravtansine (MIRV) is an antibody-drug conjugate approved for the treatment of ovarian cancer. However, real-world data on its safety and effectiveness in routine clinical practice are limited, especially in the Chinese patient population. MIRAS is a multicenter, prospective，observational, real-word study of Mirvetuximab Soravtansine in patients of Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer with expression of Folate Receptor α.This study aims to evaluate the real-world safety and efficacy of MIRV in patients with advanced ovarian cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer that expresses folate receptor alpha (FRα). Data will be collected from medical records of patients who received MIRV as part of their routine clinical care.

Studieoversigt

Status

Ikke rekrutterer endnu

Betingelser

Intervention / Behandling

Detaljeret beskrivelse

This prospective, multicenter, observational cohort study aims to evaluate the real-world safety and effectiveness of mirvetuximab soravtansine (MIRV) in patients with advanced ovarian cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer with folate receptor alpha (FRα) expression.

Approximately 400 patients are planned to be enrolled from approximately 40 centers in China. On Day 1 of each 21-day cycle (every 3 weeks, Q3W), all patients will receive mirvetuximab soravtansine at a dose of 6 mg/kg based on adjusted ideal body weight (AIBW), either as monotherapy or in combination with other anticancer agents per clinical guideline recommendations. The starting dose may be adjusted by the investigator based on the patient's actual clinical condition. Treatment will continue until disease progression, unacceptable toxicity, withdrawal of consent, loss to follow-up, death, or other protocol-specified events requiring treatment discontinuation, whichever occurs first.

The screening period is up to 28 days. Safety assessments, including laboratory tests, ECOG performance status, vital signs, physical examinations, ophthalmologic examinations, adverse events, and concomitant medications, will be conducted every 3 weeks (± 1 week) during treatment. Tumor imaging assessments by CT or MRI per RECIST v1.1 will be performed every 2-3 cycles (± 7 days) to evaluate treatment response. Serum CA125 will be assessed within 14 days prior to the first dose, before each MIRV administration, and at each tumor imaging assessment (± 4 days).

For patients who permanently discontinue MIRV treatment, an end-of-treatment visit will be conducted within 7 days, followed by a safety follow-up visit 30 days (± 2 to +14 days) after the last dose. Survival follow-up will be conducted every 3 months (± 1 month) thereafter until death, loss to follow-up, withdrawal of survival follow-up consent, or end of study, whichever occurs first.

All data will be collected from routine clinical practice, entered into an electronic data capture (EDC) system, and analyzed using descriptive statistics. Time-to-event endpoints will be estimated using the Kaplan-Meier method. No additional interventions or study-mandated procedures are required beyond standard of care. This study is strictly observational and does not involve any investigational new drug application (IND) with the U.S. FDA.

Undersøgelsestype

Observationel

Tilmelding (Anslået)

400

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Prøveudtagningsmetode

Ikke-sandsynlighedsprøve

Studiebefolkning

Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer or Primary Peritoneal Cancer With Expression of Folate Receptor α

Beskrivelse

Inclusion Criteria:

  • Patients who meet all of the following inclusion criteria are eligible to participate in the study:

    1. Female patients aged ≥18 years.
    2. Patients must have histologically confirmed epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    3. Patients must have PD on or after the most recent anti-cancer therapy.
    4. Patients must have FRα expression confirmed by VENTANA FOLR1 (≥ 25% of tumor cells with intensity ≥ 2 + after FRα staining).
    5. Patients must have normal major organ function and be suitable for MIRV monotherapy or combination therapy according to clinical recommendations
    6. Patients must have at least 1 evaluable lesion per RECIST v1.1 (radiologically assessed by the investigator).
    7. Eastern Cooperative Oncology Group Performance Status (ECOG PS) score must be 0-2.
    8. All toxicities (except alopecia) associated with prior therapy must have recovered to ≤ Grade 1 per CTCAE v5.0.
    9. Patients must have had completed any major surgery at least 4 weeks prior to the first dose of MIRV, and have recovered or stabilized from postoperative complications of prior surgery.
    10. Patients must have expected survival of at least 12 weeks as assessed by the investigator.
    11. Patients must sign ICF, and willingness and ability to comply with the study protocol, including scheduled treatment, regular follow-up, and examinations.

Exclusion Criteria:

  • Patients who meet any of the following criteria may not be enrolled in the study:

    1. Participation in other clinical studies during the same period.
    2. Patient with known prior hypersensitivity to monoclonal antibody therapy or maytansinoids, or to study drug and/or any of its excipients.
    3. Patients with active or chronic corneal disorders, history of corneal transplant, or active ocular conditions requiring ongoing treatment/monitoring such as uncontrolled glaucoma, wet age-related macular degeneration requiring treatment with intravitreal injections, active diabetic retinopathy with macular edema, macular degeneration, presence of papilledema and/or monocular vision.
    4. Patients with prior treatment with MIRV or other FRα-targeting agents. (Only for patients in prospective cohort)
    5. Pregnant or breast-feeding females. Women of childbearing potential must agree to use highly effective contraception while using study drug and for at least 7 months after the last dose of MIRV.
    6. Current participation in any interventional study other than routine clinical practice.
    7. Any other condition that, in the investigator's judgment, makes the patient unsuitable for participation in this study

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

Kohorter og interventioner

Gruppe / kohorte
Intervention / Behandling
All Enrolled Patients Receiving MIRV-Based Therapy
This cohort includes all enrolled patients with FRα-expressing advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer who receive mirvetuximab soravtansine (MIRV)-based therapy in routine clinical practice. Patients may receive MIRV as monotherapy or in combination with other anticancer agents per physician's discretion and clinical practice guidelines.
Medicin: Mirvetuximab Soravtansine (MIRV)
The recommended dose of MIRV is 6 mg/kg based on adjusted ideal body weight (AIBW), administered intravenously on Day 1 of each 21-day cycle. Investigators may adjust the starting dose based on the patient's actual clinical condition. Premedication including antipyretics, antihistamines, corticosteroids, and antiemetics is administered prior to each infusion to reduce infusion-related reactions and gastrointestinal adverse events. Prophylactic corticosteroid eye drops and artificial tears are used to manage ocular toxicity. Treatment continues until disease progression, unacceptable toxicity, withdrawal of consent, death, or study termination, whichever occurs first. Dose reductions (to 5 mg/kg or 4 mg/kg AIBW) are permitted for management of adverse events per protocol-specified criteria.
Andre navne:
  • Elahere

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Incidence of Grade ≥ 3 Treatment-Related Adverse Events (TRAEs)
Tidsramme: From first dose to 30 days after last dose of MIRV
Incidence of Grade 3 or higher treatment-related adverse events (TRAEs) assessed by the investigator
From first dose to 30 days after last dose of MIRV

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Investigator-assessed objective response rate (ORR)
Tidsramme: From first dose until disease progression, up to approximately 24 months
Objective response rate defined as the proportion of patients with confirmed complete response (CR) or partial response (PR) per RECIST v1.1, assessed by investigators, with responses confirmed at least 4 weeks after initial response
From first dose until disease progression, up to approximately 24 months
Investigator-assessed duration of response (DOR)
Tidsramme: From first documented response to disease progression or death, up to approximately 24 months.
DOR defined as the time from first documented CR or PR (whichever occurs first) to disease progression according to RECIST v1.1 or death, whichever occurs first, assessed by investigators.
From first documented response to disease progression or death, up to approximately 24 months.
Investigator-assessed progression-free survival (PFS)
Tidsramme: From first dose to disease progression or death, up to approximately 24 months.
PFS defined as the time from the first dose to the first documented PD or death due to any cause, whichever occurs first, during the tumor assessment follow-up visit.
From first dose to disease progression or death, up to approximately 24 months.
Overall survival (OS)
Tidsramme: From first dose to death from any cause, up to approximately 36 months.
OS defined as the time from the first dose to death due to any cause (for patients who have been lost to follow-up prior to death, the time of last follow-up is usually used as the time of death).
From first dose to death from any cause, up to approximately 36 months.
CA125 response
Tidsramme: From first dose until disease progression, assessed per GCIG criteria, up to approximately 24 months.
CA125 response defined as a reduction in serum CA125 levels according to Gynecologic Cancer Intergroup (GCIG) criteria.
From first dose until disease progression, assessed per GCIG criteria, up to approximately 24 months.
Incidence, severity and duration of treatment emergent adverse events (TEAEs) and TRAEs
Tidsramme: From first dose to 30 days after last dose of MIRV.
Incidence, severity, duration, and dose modifications of treatment-emergent adverse events (TEAEs) and treatment-related adverse events (TRAEs) assessed by investigators per CTCAE v5.0.
From first dose to 30 days after last dose of MIRV.

Andre resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
MIRV Treatment Patterns
Tidsramme: Baseline and throughout treatment period.
Treatment patterns including patient characteristics at baseline, combination therapy regimens, and starting dose distribution.
Baseline and throughout treatment period.
Progression-Free Survival 2 (PFS2) and Subsequent Therapy
Tidsramme: From first dose to progression on subsequent therapy or death, up to approximately 36 months.
Subsequent therapy after progression on MIRV and progression-free survival 2 (PFS2), defined as the time from first dose to progression on subsequent therapy or death.
From first dose to progression on subsequent therapy or death, up to approximately 36 months.

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

NING LI-GYN

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

20. juli 2026

Primær færdiggørelse (Anslået)

30. september 2028

Studieafslutning (Anslået)

30. september 2028

Datoer for studieregistrering

Først indsendt

1. juli 2026

Først indsendt, der opfyldte QC-kriterier

1. juli 2026

Først opslået (Faktiske)

8. juli 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

8. juli 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

1. juli 2026

Sidst verificeret

1. juli 2026

Mere information

Begreber relateret til denne undersøgelse

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • MIRV-20260305

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Livmoderhalskræft

Kliniske forsøg med Mirvetuximab Soravtansine (MIRV)

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Pakistan

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

3
Abonner